Emerson Electric Company (EMR) Stock Price & How to Invest

Emerson Electric is a global industrial-technology company focused on automation, helping manufacturers and process industries run their plants more efficiently, safely, and reliably. Over the past several years Emerson has transformed itself from a diversified industrial conglomerate into a more focused automation pure-play, divesting legacy businesses like its commercial and residential climate-technologies unit and acquiring software and measurement assets. Its core products include process control systems, measurement and analytical instruments, valves and actuators, software for plant operations, and test and measurement equipment, much of it sold under brands like DeltaV, Rosemount, Fisher, AspenTech, and NI (National Instruments). Customers span energy, chemicals, life sciences, power, water, food and beverage, and discrete manufacturing. Emerson makes money by selling this hardware and software plus recurring service, software subscriptions, and aftermarket parts, with a meaningful share of revenue tied to keeping installed systems running. The shift toward higher-margin software and recurring revenue, anchored by its majority stake in AspenTech, is central to its strategy. Emerson is headquartered in St. Louis, Missouri.

Emerson's end markets are cyclical and tied to industrial capital spending, energy and chemical capex, and the global economy, so downturns can slow orders and revenue. The transformation through large acquisitions like AspenTech and NI carries integration, execution, and valuation risk, and the company took on debt and complexity to fund deals. Competition in automation and industrial software is intense, including from larger and lower-cost rivals. Foreign-exchange effects, supply-chain disruptions, and project delays can pressure results. The stock can be volatile around portfolio moves and macro cycles, and the payoff from the software pivot must still prove out fully.

27 analysts publish price targets on EMR, averaging $163.54 against a $147.21 price as of July 2026, or +11.1%. The published targets run from $104.00 to $203.00, a moderate spread, and the ratings split 20 buy, 7 hold, 2 sell. Over the last six months there have been 5 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full EMR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Emerson Electric Company. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Automation pure-play transformation. Emerson has reshaped itself into a focused automation company by divesting non-core units and concentrating on process and industrial automation. The most optimistic published target, $203.00, assumes this works close to its best case.

The case against. Emerson's end markets are cyclical and tied to industrial capital spending, energy and chemical capex, and the global economy, so downturns can slow orders and revenue. The most pessimistic target, $104.00, is roughly what EMR is worth if this bites instead.

Read the full bull and bear case on EMR, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Emerson Electric Company's investor relations page or your broker.

• Revenue (TTM): ~$17-18 billion
• Operating margin: ~20%+, expanding
• Revenue growth: Mid-single-digit underlying, plus acquisitions
• Software and recurring mix: Growing share of revenue
• P/E (TTM): Above the average industrial
• Dividend yield: Modest, ~1.7%, a Dividend King
• Free cash flow: Strong, high conversion
• Dividend history: Decades of consecutive increases

Emerson trades at a premium to the average industrial, reflecting its transformation into a higher-margin automation and software business and its anchor stake in AspenTech. The market values the recurring-revenue mix, margin expansion, and strong cash generation, while weighing acquisition and integration risk. Its Dividend King status and steady cash flow underpin a quality-industrial profile.

If you want EMR exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses EMR naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to EMR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get EMR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (PAVE, IFRA), which spreads the position across many companies. Or build it into a focused thematic portfolio, so EMR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where EMR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Emerson Electric (EMR) is a leading automation and industrial-software company whose AspenTech and NI deals shift it toward stickier, higher-margin recurring revenue, supported by reshoring and energy-transition spending. In a portfolio it behaves as a quality-industrial dividend-growth anchor that still carries cyclical end-market exposure, acquisition-integration risk, and a premium-to-peer valuation.

Whether EMR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is EMR a buy or a sell?, and where the stock could go from here in the EMR stock forecast.

For income investors, whether EMR pays a dividend and how the payout looks is covered in does EMR pay a dividend? And to weigh EMR against a peer, read the full side-by-side comparisons: EMR vs ROK and EMR vs ABB.